briakinumab

English

Etymology

From -kin- (“interleukin”) +‎ -umab (“human monoclonal antibody”).

(This etymology is missing or incomplete. Please add to it, or discuss it at the Etymology scriptorium.)

Noun

briakinumab (uncountable)

  1. (pharmacology) A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
    • 2015 December 4, “Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients”, in PLOS ONE‎[1], →DOI:
      As another interleukin 12/23 antagonist, briakinumab, was withdrawn from further development in part due to concerns about cardiovascular safety, discussion has also emerged on cardiovascular safety of ustekinumab.